Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai, Osaka Univ. Clinch 10 Billion Yen Immunology Pact
May 20, 2016
- Ono Ties Up with Univ. of Tokyo Venture for Antibody Drug
May 19, 2016
- Suzuken Outstrips Medipal in Drug Wholesaling Biz on Hep C Boom: Jiho Tally
May 19, 2016
- Takecab Most Heavily Pitched Drug for 3 Consecutive Months: Anterio
May 18, 2016
- Harvoni Tops Japan Yearly Sales Ranking Only 7 Months after Launch: IMS
May 18, 2016
- ASKA Dissolves Generic JV with Actavis
May 17, 2016
- Medipal to Set Up Subsidiary for Specialty Drugs
May 17, 2016
- Lilly, Kanazawa Medical Univ. Ink Research Deal on Diffuse-Type Gastric Cancer
May 17, 2016
- Top 8 Japan Drug Makers Relish 2.6-Fold Operating Profit Jump on Global Brands
May 17, 2016
- Chugai’s CellCept, Generic Versions Approved for Lupus Nephritis
May 17, 2016
- Nippon Kayaku Faces Damage Suit over Elplat Patent
May 17, 2016
- Santen Anticipates Continued Growth in Sales of Ikervis in Europe; 30% Overseas Sales Ratio an “Achievable Target”
May 17, 2016
- As Tagrisso Launch Nears, AZ Pushes Stringent Prerequisites for Facilities, Doctors to Ensure Safety
May 17, 2016
- Towa to Mull Over Distribution Dealing with Wholesalers
May 17, 2016
- Eisai Aims for 10% Rise in Japan Pharma Sales with Patented Products: CEO
May 16, 2016
- Eisai Posts Higher Profits despite Sales Dip, Global Brands Expand
May 16, 2016
- Kyorin Enthusiastic about Overcoming “Kipres Cliff,” Aiming for Over 50% Share with AG, 4 New Product Launches
May 16, 2016
- Ono to Erect New Opdivo Plant, Operational Launch Eyed for 2020
May 13, 2016
- US Merck Links Up with Univ. of Tokyo on Drug Discovery
May 13, 2016
- Takeda Taps Ex-Kraft Foods CFO Kehoe as New CFO
May 13, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…